Availability and Use of Essential Medicines in China: Manufacturing, Supply, and Prescribing in Shandong and Gansu Provinces by Tang, Shenglan et al.
 
Availability and Use of Essential Medicines in China:
Manufacturing, Supply, and Prescribing in Shandong and Gansu
Provinces
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Chen, Wen, Shenglan Tang, Jing Sun, Dennis Ross-Degnan, and
Anita K. Wagner. 2010. Availability and use of essential
medicines in China: manufacturing, supply, and prescribing in
Shandong and Gansu provinces. BMC Health Services Research
10:211.
Published Version doi:10.1186/1472-6963-10-211
Accessed February 19, 2015 4:40:08 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:4621010
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAAChen et al. BMC Health Services Research 2010, 10:211
http://www.biomedcentral.com/1472-6963/10/211
Open Access RESEARCH ARTICLE
© 2010 Chen et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Research article Availability and use of essential medicines in China: 
manufacturing, supply, and prescribing in 
Shandong and Gansu provinces
Wen Chen*1, Shenglan Tang2,3, Jing Sun4, Dennis Ross-Degnan5 and Anita K Wagner5
Abstract
Background: The current health care reform in China launched in 2009 tackles the problem of access to appropriate 
medicines for its 1.3 billion people by focusing on providing essential medicines to all. To provide evidence for the 
reform process, we investigated the manufacturing, purchasing, and prescribing of essential medicines in two 
provinces.
Methods: We conducted surveys in 2007 of all manufacturers (n = 253) and of 59 purposively selected retail and 63 
hospital pharmacies in Shandong and Gansu provinces to assess production and supply of products on the 2004 
National Essential Medicines List (NEML), as well as factors underlying decision making about production and supply. 
We also reviewed prescriptions (n = 5456) in health facilities to calculate standard indicators of appropriate medicines 
use.
Results: Overall, manufacturers in Shandong and Gansu produced only 62% and 50%, respectively, of the essential 
medicines they were licensed to produce. Of a randomly selected 10% of NEML products, retail pharmacies stocked up 
to 60% of Western products. Median availability in hospital pharmacies ranged from 19% to 69%. Manufacturer and 
retail pharmacy managers based decisions on medicines production and stocking on economic considerations, while 
hospital pharmacy managers cited clinical need. Between 64% and 86% of prescriptions contained an essential 
medicine. However, overprescribing of antibiotics (34%-77% of prescriptions) and injectables (22%-61%) for adult non-
infectious outpatient consultations was common.
Conclusions: We found that manufacturers, retail pharmacies, and hospital pharmacies paid limited attention to 
China's 2004 NEML in their decisions to manufacture, purchase, and stock essential medicines. We also found that 
prescribing of essential medicines was frequently inappropriate. These results should inform strategies to improve 
affordable access to essential medicines under the current health care reform.
Background
China spent 4.5% of Gross Domestic Product (GDP) on
health care in 2007 [1]. Although total health care expen-
ditures have been modest relative to GDP , pharmaceuti-
cal expenditures account for a significant proportion,
averaging over 40% during the past two decades [1]. In
contrast, the average percentage in OECD countries was
around 15% [2].
Despite high pharmaceutical spending, China experi-
ences substantial problems in access to medicines, due
both to the lack of availability of essential medicines and
to the high cost of and preference for branded products
[3]. Perverse financial incentives to service providers lie
at the core of these problems. A large proportion of hos-
pital revenue comes from profits from pharmaceutical
sales, often the most important source of income at
county and lower level hospitals and health centers [4,5].
Service providers make greater profits on higher priced
pharmaceuticals, since the mark-up rate is fixed by gov-
ernment regulation. Hence, Chinese doctors tend to
overprescribe medicines, in particular expensive medi-
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cines, to maximize revenue generation for their institu-
tions and bonus payments for themselves [5,6].
For over 30 years, the WHO has advocated an essential
medicines list for member states [7]. Every two years
since 1977, WHO has updated the WHO Model List of
Essential Medicines of about 300 products, which coun-
tries are expected to adapt to their needs [8]. China's
Ministry of Health developed its first National Essential
Medicine List (NEML) in 1981, aiming to ensure the ade-
quate supply, distribution, and rational use of essential
medicines. The 2004 NEML consisted of 1260 Chinese
herbal preparations and 773 chemical and biological
medicines products. However, appropriate supporting
policies and mechanisms needed for the NEML to
achieve its intended objectives have been lacking in the
areas of manufacturing, supply, reimbursement and use
of essential medicines [3].
To guide the pharmaceutical sector, Chinese authorities
have formulated a series of policies on pharmaceutical
research and development, product approval, produc-
tion, distribution, utilization, pricing, and insurance cov-
erage [9]. Of these, price management and insurance
coverage have been the two most important measures
influencing availability and use of essential medicines.
Controls on medicine pricing have been promulgated 27
times since 1997, but the measures have not had signifi-
cant impact in reducing financial burden for service
users. One reason is that manufacturers stop producing
medicines that no longer yield targeted profits, and hos-
pitals and doctors are not keen to use them for similar
reasons [9-11].
Few studies have examined the availability and use of
essential medicines in China, one of four key health sec-
tor components targeted in China's ambitious 2009
health system reform plan. In this paper, we provide evi-
dence to answer the following research questions: To
what extent are essential medicines produced by Chinese
manufacturers and how available are these medicines in
retail and hospital pharmacies? How frequently and
appropriately are essential medicines prescribed in Chi-
nese health facilities?
Methods
We conducted the current study in Shandong and Gansu
provinces, which are representative of the eastern (more
developed) and western (less developed) regions of
China, respectively. To understand availability of essential
medicines, we conducted surveys in 2007 of manufactur-
ers, hospitals, and retail pharmacies. To understand med-
icines use patterns, we reviewed a sample of prescriptions
in selected hospitals. Table 1 contains an overview of the
information collected from each data source. The study
was funded by the WHO, which agreed to the use of
these data for academic research.
Manufacturer survey
For the purpose of this survey, all manufacturers in Shan-
dong and Gansu provinces registered with the SFDA
were requested to report to the SFDA the essential medi-
cines which they were licensed to produce and those
which they actually produced in 2004 and 2005. We did
not obtain data on non-essential medicines production.
In structured interviews, we also asked the chief execu-
tives of these manufacturers which factors most influ-
enced their essential medicines production decisions.
Health facility pharmacy survey
We selected representative, non-random samples of 10%
of the primary, secondary, and tertiary care hospitals in
each province. Hospital levels differ by technical capacity.
Primary hospitals (known as urban community health
care centers and rural township hospitals) deliver com-
prehensive primary care and limited inpatient care for
common diseases. Secondary hospitals (known as urban
district hospitals and rural county hospitals) are responsi-
ble for basic medical care, emergency care, and technical
instruction to physicians in primary hospitals. Tertiary
hospitals provide diagnosis and treatment for complex
diseases and technical instruction to secondary hospitals.
In each facility, we reviewed 2006 pharmacy purchasing
records to assess the percentage of essential medicines
among all Western medicines purchased. We also
assessed the availability in pharmacy stocks of selected
essential medicines (see below). Using structured ques-
tionnaires, we interviewed pharmacy managers about
their reasons for purchasing and stocking essential medi-
cines.
Retail pharmacy survey
Although hospital pharmacies dispense prescribed medi-
cines for most outpatients, retail pharmacies, which are
managed by licensed pharmacists, can also dispense OTC
and prescription medicines. We divided all prefectural
level cities in the two study provinces into those with
high, middle, and low average GDP per capita. We ran-
domly selected one study city to represent each socioeco-
nomic group; in each city, we purposively selected two
pharmacies contracted to dispense medicines to insured
patients and three pharmacies without insurance con-
tracts. We then purposively selected one middle GDP
county (the administrative level below the prefectural
level) in each study city; in each county, we selected five
representative retail pharmacies. In total, we surveyed 59
retail pharmacies, 30 in Shandong and 29 in Gansu.
In study pharmacies, we assessed availability of a sam-
ple of essential medicines (see below). Study personnel
visited each pharmacy to collect these data and to inter-
view pharmacy managers about their rationale for pur-Chen et al. BMC Health Services Research 2010, 10:211
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chasing and stocking essential medicines and about their
understanding of the essential medicines concept.
Selection of survey medicines
To assess availability of essential medicines in retail and
hospital pharmacies, we randomly selected 40 Chinese
medicines (107 unique dosage forms) and 77 Western
medicines (98 unique dosage forms) from the 1260 Chi-
nese and 773 Western medicines listed on the 2004
NEML. Since product strength is not indicated on the
NEML, we included any available strength of the sample
of W estern medicines. Although the availability of Chi-
nese herbal preparations improves access to essential
medicines, especially in rural primary health care institu-
tions, Western medicines are the treatment of choice for
the majority of Chinese patients.
Prescription review
Using clinic records, we reviewed outpatient prescrip-
tions in each study hospital on a random day in 2006, fol-
lowing survey methods recommended by WHO for
investigating prescribing in health facilities [12]. This sur-
vey sought to characterize the overall rate of prescribing
of medicines from the NEML in routine adult outpatient
care, as well as the rates of specific potentially inappropri-
ate prescribing practices, including polypharmacy and
overprescribing of antibiotics and injections. We system-
atically selected 100 prescriptions in each facility. If fewer
than 100 prescriptions were issued, we included all pre-
scriptions issued on the study day. To assess prescribing
of Western medicines, we excluded herbal products. T o
examine potential overprescribing of antibiotics and
injections in routine adult outpatient care, we excluded
prescriptions for children, adult emergency care, and
adult cases treated in hospital infectious disease clinics.
Data analysis
Data were analyzed using SPSS version 13.0. We summa-
r i z e  d a t a  o n  p r o d u c t i o n  a s  t h e  p e r c e n t a g e  o f  l i c e n s e d
essential medicines manufactured and identify the 10
most frequently manufactured essential medicine prod-
ucts. We summarize the supply of essential medicines in
pharmacies by category (Chinese and Western medicines
on the NEML). We list the factors most frequently cited
by enterprise chief executives and pharmacy managers
when deciding on producing or procuring essential medi-
cines, respectively. We also describe the frequency of
inappropriate prescribing using standard indicators of
quality use of medicines [13].
Results
Manufacturing of essential medicines
Shandong manufacturers averaged 20 essential medicine
product licenses in 2005, with about 60% of licensed
products actually produced (Table 2). In Gansu, manufac-
turers averaged 41 licenses but only 50% of the products
were manufactured in 2005. The proportion of essential
medicines produced was not associated with manufac-
turer sales volumes. Among manufacturers that failed to
report sale volumes, the proportion of licensed products
actually produced was very low (1.1%).
In Shandong and Gansu provinces, respectively, the five
factors mentioned by manufacturers as most influential
on their production decisions were market demand (81%,
94%), production cost (79%, 89%), price (65%, 50%), mar-
ket share (54%, 56%), and profit margin (54%, 53%).
Table 1: Data sources for manufacturer, pharmacy, and prescription surveys
Provinces (population, n) Shandong (92 million) Gansu (17 million)
Manufacturers, n 217 36
Hospital level of care Primary Secondary Tertiary Primary Secondary Tertiary
Study hospitals, n 15 17 8 7 11 5
Prescriptions surveyed, n 982 1687 800 414 1078 495
Prefecture GDP/capita High Middle Low High Middle Low
Study retail pharmacies at city-level, n
With insurance contracts 2 2 2 2 2 2
Without insurance contracts 3 3 3 3 3 3
Study retail pharmacies at county level, n 5 5 5 5 5 4Chen et al. BMC Health Services Research 2010, 10:211
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Whether or not the medicines were listed as reimburs-
able by the social health insurance (32%, 25%) or listed in
the NEML (20%, 25%) were less important.
At least one manufacturer produced 579 (28.5%) and
230 (11.3%) of the essential medicine products on the
2004 NEML in Shandong and Gansu provinces, respec-
tively. The most frequently produced product was glu-
cose injection (produced by 117 manufacturers in
Shandong and 18 in Gansu). In Shandong, of the ten most
frequently manufactured products, eight were Western
medicines and six of those were injections. Paracetamol
tablets, a widely used pain reliever for adults and chil-
dren, was among the ten most frequently licensed prod-
ucts (by 36 manufacturers), but not among the ten most
frequently manufactured ones (produced by ten manu-
facturers). Among the ten most frequently manufactured
products in Gansu, glucose injection was the only West-
ern medicine (Table 3).
Supply of essential medicines
Retail pharmacies
Of the 140 Western essential medicine products ran-
domly sampled from the NEML, 49 (35%) and 69 (49%)
were not available in any investigated retail pharmacy in
Shandong and Gansu, respectively. Among the 41 NEML
products not found in either province, 21 were injections,
including diagnostics like technetium and iodohippurate,
as well as products like potassium phosphate which
require administration in hospital settings. However,
essential medicines like salbutamol and sodium valproate
syrups, used to treat asthma and epilepsy in children,
respectively, were also not available. About two-thirds of
the pharmacies stocked only 17% and 12% of the selected
essential Western medicines in Shandong and Gansu,
respectively.
Of 107 essential traditional Chinese medicines, 7 (7%)
and 19 (18%) products were not for sale in Shandong and
Gansu provinces, respectively, including five which were
not available in either province. About two-thirds of the
pharmacies stored 45% and 46% of Chinese products in
Shandong and Gansu, respectively.
Pharmacy managers in Shandong and Gansu reported
that the top four factors determining their procurement
decisions were market demand (90%, 100% respectively),
price (90%, 83%), profit margins (73%, 45%) and market
share (53%, 45%). Whether or not medicines are reim-
bursable by the social health insurance (33%, 34%) or
listed in the NEML (10%, 21%) were again less important.
In addition, more than 40% of pharmacy managers in
each province did not know the NEML and 60% did not
consider it in purchasing decisions.
Hospital pharmacies
Essential medicine products constituted 67% (standard
deviation (SD) 27%), 72% (SD 22%), and 80% (SD 10%) of
the Western medicine products purchased in 2006 by pri-
mary, secondary, and tertiary care hospital pharmacies in
Shandong, respectively. Of the random sample of essen-
tial medicines products, pharmacies in Shandong pri-
mary care hospitals supplied a median of 26% and tertiary
care hospitals 69% of the Western medicines on the
NEML; in Gansu, these figures were lower at 19% and
38% respectively (Table 4). However, supply in Shandong
varied widely. One hospital pharmacy had less than 20%
of the sampled Western essential medicines, while
Table 2: Essential medicines production as percentage of licenses held by manufacturers in Shandong and Gansu 
provinces in 2005, by manufacturer sales volume
Annual sales 
volume, RMB*
Shandong Gansu
Manufacturers, n Essential 
medicines 
licenses held, n
Licensed 
essential 
medicines 
produced, n (%)
Manufacturers, n Essential 
medicines 
licenses held, n
Licensed 
essential 
medicines 
produced, n (%)
Less than 10 
million
54 440 271 (62) 13 262 102 (39)
10-30 million 51 778 463 (60) 12 610 306 (50)
30-100 million 48 1117 665 (60) 5 455 273 (60)
100-500 million 35 1292 872 (67) 3 136 57 (42)
More than 500 
million
12 622 399 (64) 0 0 0
Unknown 17 91 1 (1) 3 26 0
Total 217 4340 2671 (62) 36 1489 737 (50)
* On Jan 1, 2007, near the time of the survey, the conversion rate was RMB 7.80 to $US 1.00.Chen et al. BMC Health Services Research 2010, 10:211
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another had more than 80%. Regardless of hospital level,
half of the pharmacies carried about 25% of the Chinese
NEML products. In Gansu province, no hospital phar-
macy stocked more than 60% of Western essential medi-
cines. Six NEML products were not available in any
surveyed hospital pharmacy in both provinces (pipotiaz-
ine injection, capreomycin injection powder, ritonavir
oral liquid, compound salvia miltiorrhiza pills, niuhuang
shangqing capsule, and buzhong yiqi decoction).
The most frequent reason for not purchasing the
selected essential medicines across hospital levels was
lack of clinical use for the products (in Shandong 64%,
58%, and 52% and in Gansu 62%, 69%, and 70% of pri-
mary, secondary, and tertiary hospitals, respectively), fol-
lowed by availability of clinical alternatives (Shandong:
31%, 32%, 41%; Gansu: 28%, 28%, 22%).
Prescribing of essential medicines
Overall, as shown in Table 5, the average number of med-
icines prescribed per patient was lower in Shandong
province and decreased by hospital level (an average of
3.2 medicines in primary, 2.5 in secondary, and 2.0 in ter-
tiary level hospitals in Shandong, compared to 5.3, 3.9,
and 2.6 in Gansu). However, despite prescribing fewer
medicines, the costs per prescription (and thus cost per
medicine) increased substantially by hospital level.
While the percentages of essential medicines pre-
scribed ranged from 64% in tertiary facilities in Shandong
to 86% in primary hospitals in Gansu, large proportions
of prescriptions contained an antibiotic (between 34% in
tertiary care hospitals in Shandong and 77% in primary
care hospitals in Gansu) or an injection (from 22% in ter-
tiary care to 61% in primary care hospitals in Gansu). The
percentages of prescriptions containing an antibiotic or
injection were higher at lower levels of hospital care in
both provinces.
Discussion
Our analyses showed that manufacturers in Shandong
and Gansu provinces did not produce at least 40% of the
products on the 2004 NEML for which they held produc-
tion licenses, with their production decisions determined
primarily by economic considerations. Many essential
medicines are not perceived as profitable because of low
demand, as well as price and mark-up controls.
Table 3: Top 10 essential medicines products manufactured in 2005
Shandong Gansu
Medicine (name, 
dosage form)
Manufacturers with 
license, n
Manufacturers 
producing, n
Medicine (name, 
dosage form)
Manufacturers with 
license, n
Manufacturers 
producing, n
Glucose injection 177 117 Glucose injection 20 18
Sodium chloride 
injection
96 64 Xiaoyao pills 22 17
Glucose and sodium 
chloride injection
88 59 Liu Wei Di Huang pills 20 17
Banlangen granule 31 25 Bao He pills 17 14
Vitamin C injection 57 23 Gui Fu Di Huang pills 17 13
Metronidazole tablet 36 22 Bu Zhong Yi Qi pills 21 12
Norfloxacin capsule 37 21 Guipi pills 16 12
Ribavirin injection 35 21 Cen Su pills 15 12
Liu Wei Di Huang pills 30 21 Fuzi Lizhong pills 17 11
Metronidazole 
injection
29 20 Huang Lian Shang 
Qing pills
16 11Chen et al. BMC Health Services Research 2010, 10:211
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Most retail pharmacies stocked less than 20% and most
hospital pharmacies between 20% and 74% of a random
sample of Western products on the NEML, depending on
the province and hospital level of care. While retail phar-
macies cited primarily economic reasons for their pur-
chase decisions, hospital pharmacies most commonly
cite lack of clinical utilization as the reason for not stock-
ing medicines on the NEML. However, clinical and eco-
nomic motivations are closely related. Pharmacies tend to
stock what is prescribed, and prescribing is motivated in
part by financial incentives. Clinicians in hospitals favor
prescribing of higher cost medicines not subject to price
controls because they generate greater revenues. This
puts added cost burden on patients, especially for those
without insurance who pay for all medicines out of
pocket and also on both urban and rural health insurance
funds.
A fairly high percentage of the medicines prescribed in
adult hospital outpatient encounters were included on
the 2004 NEML, which is not surprising given that the list
contained 773 Western essential medicines compared to
the 300 on the WHO Model Essential Medicines List.
Antibiotics and injections were very commonly pre-
scribed. WHO estimates that guideline-based care would
result in rates of antibiotic use in routine outpatient care
of 20% or less and rates of injection use of 5% or less [12].
A recent WHO global review reported that the median
rates of outpatient antibiotic and injection prescribing
were 46% and 19%, respectively, for all published studies
conducted between 2004 and 2006 [14]. These compare
with the observed rates of antibiotic prescribing of 45% in
Shandong and 59% in Gansu, and rates of injection pre-
scribing of 34% and 38% in the two provinces, respec-
tively. Thus, overprescribing of antibiotics and injections
in these two provinces is particularly inappropriate, in
light of global standards.
Our study has several limitations. We did not collect
data on non-essential products manufactured and thus
we cannot assess the proportion of essential medicines
manufactured among all medicines produced. We
assessed supply of a sample of NEML medicines, rather
than all NEML products. Although we randomly sampled
NEML medicines, it is possible that this sample is not
representative of all essential medicines. In addition,
since the NEML does not specify whether medicines are
appropriate for inpatient or outpatient care, some of the
NEML medicines may not be expected to be stocked in
retail pharmacies. Lastly, because we did not have diag-
nostic information related to individual prescriptions, we
could not assess appropriateness of prescribing in rela-
tionship to the condition treated.
These limitations not withstanding, the present data
illustrate key challenges faced by the Chinese health care
system. First, there are competing interests between the
pharmaceutical industry's profit orientation and the gov-
ernment's objective of securing access to affordable
essential medicines for the public. Over the past three
decades, provincial and municipal governments have
promoted the pharmaceutical industry as a pillar for eco-
nomic growth and job creation [9,15], without emphasiz-
ing its responsibility in helping to secure access to
essential medicines.
Second, the current medicines pricing system has failed
to stimulate competition in the production of essential
medicines. The pricing authority strictly controls the
price of generics, while allowing higher prices for
branded generics and much higher prices for originator
products. To avoid price controls, manufacturers have
shifted registration and marketing to branded generics.
The data from Shandong province, where the pharma-
ceutical industry is an important component of the econ-
omy [16], show that manufacturers give priority to
Table 4: Availability (median percentage, 25th, 75th percentiles) of selected essential medicines in the sample of hospital 
pharmacies
Shandong Gansu
Hospital Level of Care NEML-Chinese NEML-Western NEML-Chinese NEML-Western
Primary 25% 26% 33% 19%
(21%, 36%) (23%, 30%) (17%, 33%) (16%, 20%)
Secondary 23% 47% 29% 30%
(20%, 33%) (45%, 51%) (22%, 34%) (24%, 34%)
Tertiary 23% 69% 23% 38%
(21%, 29%) (61%, 74%) (22%, 24%) (37%, 43%)Chen et al. BMC Health Services Research 2010, 10:211
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Western injectable products, among the more expensive
products on the NEML.
Third, hospitals and doctors have no incentives to use
relatively inexpensive generic essential medicines [9,11].
Since Government funding only accounts for about 10%
of hospital funding [17], hospitals and health care provid-
ers have relied on out of pocket payments by individual
patients or health insurance reimbursement. Health facil-
ities generate greater profits through prescribing of medi-
cines with high markups not subject to price control. The
more medicines doctors prescribe, the higher the income
hospitals and doctors receive [5]. Such perverse incen-
tives have been a major obstacle in promoting rational
use of medicines.
Consistent with other studies [18,19], we find that
essential medicines constitute a reasonably high propor-
tion of the medicines prescribed in hospitals. However,
some prescribing of essential medicines can be inappro-
priate, such as prescribing injections for common condi-
tions which can be safely treated with oral medicines or
antibiotics for non-bacterial conditions in which they are
not indicated. In addition to the economic incentives to
overprescribe expensive medicines, a lack of knowledge
among patients about essential medicines and the
absence of effective training on appropriate use of medi-
cines for health care professionals likely contribute to
high levels of inappropriate use.
The Chinese Government has embarked upon major
changes to overcome these challenges [20]. In August
2009, the Ministry of Health issued a new National Essen-
tial Medicines List for primary health care institutions,
consisting of 205 western generic medicines and 102 Chi-
nese herbal preparations) [21]. By 2012, all primary
health care institutions with government subsidies in
urban and rural areas will be required to stock and dis-
pense these essential medicines with zero mark up. A
maximum retail price will be set by the National Develop-
ment and Reform Commission for each essential medi-
cine and medicines with the same ingredient will have the
same price, no matter whether the product is the origina-
tor, a branded generic, or a non-branded generic. All
essential medicines will be covered by both urban and
rural insurance schemes, and these medicines will be
r ei m bursed a t  highe r r a t es.  G ive n t he  pr obl em s  in t he
supply and use of the much larger 2004 NEML observed
in this study, it will be important for the Government,
insurance schemes, and health care institutions to estab-
lish policies and incentives that facilitate the use of the
new NEML in manufacturing, purchasing, and prescrib-
ing decisions at each level of the health care system.
Conclusions
In conclusion, we found that manufacturers, retail phar-
macies, and hospital pharmacies paid limited attention to
China's 2004 NEML in their decisions to manufacture,
purchase, and stock essential medicines. We also found
that prescribing of essential medicines was frequently
inappropriate. These results should inform strategies to
improve affordable access to essential medicines under
the current health care reform.
Table 5: Indicators (mean ± SD) of outpatient medicines prescribing for routine adult outpatient consultations*
Shandong Gansu
Hospital level (number of Rx) Primary Secondary Tertiary Primary Secondary Tertiary
(982) (1687) (800) (414) (1078) (495)
Average number of medicines/Rx 3.2 ± 0.7 2.5 ± 0.4 2.0 ± 0.3 5.3 ± 2.0 3.9 ± 1.1 2.6 ± 0.5
Average cost/Rx (RMB) ** 38.6 ± 19.3 78.7 ± 27.5 101.3 ± 34.1 34.4 ± 28.3 48.2 ± 23.8 76.3 ± 16.0
% Rx with EM 72.5 ± 30.3 73.3 ± 19.3 63.8 ± 15.5 85.6 ± 25.3 78.1 ± 15.0 70.0 ± 13.1
% Rx with reimbursable medicines 76.4 ± 33.2 78.0 ± 17.0 79.3 ± 6.4 83.7 ± 26.3 77.4 ± 14.7 80.2 ± 12.7
% Rx with antibiotics 53.9 ± 9.1 45.9 ± 11.9 33.6 ± 14.0 77.2 ± 18.5 59.6 ± 8.7 40.7 ± 6.0
% Rx with injections 41.7 ± 11.2 31.8 ± 16.3 27.4 ± 16.3 61.1 ± 28.5 36.6 ± 14.0 22.3 ± 9.4
Rx = prescription
* Pediatric, adult emergency care, and infectious disease clinic consultations were excluded
** On Jan 1, 2007, near the time of the survey, the conversion rate was RMB 7.80 to USD 1.00.Chen et al. BMC Health Services Research 2010, 10:211
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